MiR-484 promotes non-small-cell lung cancer (NSCLC) progression through inhibiting Apaf-1 associated with the suppression of apoptosis

Li, Tao; Ding, Zongli; Zheng, Yulong; Wang, Wei

doi:10.1016/j.biopha.2017.09.102

Cited by 63 publications

(40 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Hu et al showed that miR-484 suppressed proliferation and epithelial-mesenchymal transition by targeting ZEB1 and SMAD2 in cervical cancer cells [25]. While, Li et al showed that miR-484 promoted non-small-cell lung cancer progression through inhibiting Apaf-1 associated with the suppression of apoptosis [26]. However, the expression and roles of miR-484 on CRC remains unclear.…”

Section: Discussionmentioning

confidence: 99%

Long non-coding RNA ZFAS1 sponges miR-484 to promote cell proliferation and invasion in colorectal cancer

Xie

Wang

et al. 2018

Cell Cycle

View full text Add to dashboard Cite

The incidence and mortality rate of colorectal cancer (CRC) have been significantly increasing. However, mechanisms involved in CRC progression are still unclear. LncRNA ZFAS1 has been verified as oncogenic molecular in a series of tumors, including CRC. However, the underlying mechanism of ZFAS1 in CRC carcinogenesis remains unclear. In the present study, our data showed that ZFAS1 expression was significantly upregulated in CRC tissues and cell lines. Correlation analysis showed that high ZFAS1 expression was significantly associated with Helicobacter pylori infection, lymph nodes metastasis, advanced TNM stage and poor overall survival of CRC patients. Loss-of-function experiments revealed that ZFAS1 inhibition could markedly suppress CRC cells proliferation and invasion both in vitro and in vivo. Bioinformatics analysis and luciferase reporter assay revealed that ZFAS1 directly interacted with miR-484. Rescue experiments showed that miR-484 inhibitor reversed the tumor suppressing roles of ZFAS1 knockdown on CRC cells. Therefore, our study suggested that ZFAS1 could act as an oncogene in CRC tumorigenesis, and discovered the functional regulatory pathway of ZFAS1 sponging miR-484.

show abstract

Section: Discussionmentioning

confidence: 99%

Long non-coding RNA ZFAS1 sponges miR-484 to promote cell proliferation and invasion in colorectal cancer

Xie

Wang

et al. 2018

Cell Cycle

View full text Add to dashboard Cite

show abstract

“…The authors concluded that these may serve as potential biomarkers for patients with NSCLC. However, to the best of our knowledge, whether serum miR-484 is differentially expressed in patients with NSCLC is yet to be elucidated, despite the fact that a high miR-484 expression has been reported in NSCLC tissue samples and cell lines (19).…”

Section: Discussionmentioning

confidence: 99%

“…The expression pattern of miR-484 has been revealed to be significantly different in various types of tumor, including breast cancer, cervical cancer and NSCLC (17,18). It has been reported that enhanced miR-484 promotes the progression of NSCLC by suppressing apoptotic protease activating factor-1 (19). However, to the best of our knowledge, whether miR-484 could be used as a potential biomarker for the early detection of NSCLC is yet to be elucidated.…”

Section: Introductionmentioning

confidence: 99%

High serum miR‑484 expression is associated with the diagnosis and prognosis of patients with non‑small cell lung cancer

2019

View full text Add to dashboard Cite

The aim of the current study was to assess the expression and clinical significance of serum microRNA (miR)-484 in patients with non-small cell lung cancer (NSCLC). Reverse transcription-quantitative polymerase chain reaction was performed to determine the expression of miR-484 in the serum of patients with NSCLC and NSCLC cell lines. Cell counting kit-8, flow cytometry, cell migration and cell invasion assays were performed to assess the role of miR-484 in the malignant changes associated with NSCLC cells. Furthermore, to assess the diagnostic value of miR-484, receiver operating curve (ROC) analysis was performed and the clinical relevance of serum miR-484 expression in patients with NSCLC was determined. A Kaplan-Meier analysis with the log-rank test was performed to assess the overall survival rate patients. To the best of our knowledge, the current study demonstrates for the first time that serum miR-484 was increased in patients with NSCLC compared with healthy controls. Additionally, serum miR-484 was revealed to be positively associated with histological grade, lymph node metastasis, distant metastasis and clinical stage. Patients with NSCLC and high serum miR-484 levels demonstrated significantly poorer overall survival rates compared with those exhibiting lower serum miR-484 expressions. ROC analysis revealed that serum miR-484 could screen patients with NSCLC patients from healthy controls with a high sensitivity and specificity. In vitro analysis also demonstrated that miR-484 was significantly upregulated in NSCLC cell lines, including 95D and H358 cells. Furthermore, the suppression of miR-484 decreased cell proliferation, cell migration and invasion. In summary, the results of the present study demonstrated that increased serum miR-484 expression is associated with the diagnosis and prognosis of patients with NSCLC. High serum miR-484 expression is associated with the diagnosis and prognosis of patients with non-small cell lung cancer

show abstract

“…miR-484 is upregulated in exosomes of BCG-infected macrophages and targets mitochondrial cleavage protein 1 to modulate the intermediate metabolic pathway 30 . Various assays have revealed that miR-484 upregulation clearly influences cell migration and cellular proliferative capacity, and miR-484 is also tumorigenic, promoting the progression of non-small cell lung cancer 31 . miR-584 is reportedly upregulated in breast cancer cells, enhancing nuclear factor kappa B signaling, and inhibiting TGF-β signaling 32 .…”

Section: Discussionmentioning

confidence: 99%

miRNA Expression Profiles and Potential as Biomarkers in Nontuberculous Mycobacterial Pulmonary Disease

Han

Jhun

Kim

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Pulmonary disease (PD) due to nontuberculous mycobacteria (NTM) is increasing globally, but specific biomarkers for NTM-PD have not been established. As circulating miRNAs are promising biomarkers for various diseases, we investigated whether miRNAs have potential as NTM-PD biomarkers. Sera from 12 NTM-PD patients due to Mycobacterium avium, M. intracellulare, M. abscessus, or M. massiliense and three healthy controls were initially evaluated via small RNA sequencing. Multiple miRNAs showed significant differences in expression in patients compared to in healthy controls, with some expression differences unique to PD caused by a specific mycobacterial species. Notably, 14 miRNAs exhibited significant expression differences in PD associated with all four mycobacteria. Validation by quantitative reverse-transcription-PCR in an additional 40 patients with NTM-PD and 40 healthy controls confirmed that four differentially expressed miRNAs (hsa-miR-484, hsa-miR-584-5p, hsa-miR-625-3p, and hsa-miR-4732-5p) showed significantly higher serum expressions in NTM-PD patients than in controls. Receiver operating characteristic curve analysis of these four miRNAs supported the discriminative potential for NTM-PD and their combination provided an improved diagnostic value for NTM-PD. Furthermore, bioinformatics analysis revealed their 125 target genes, which were mostly associated with immune responses. Collectively, this study identified four miRNAs as potential biomarkers for NTM-PD and provided insight into NTM-PD pathophysiology.Nontuberculous mycobacteria (NTM) are mycobacteria other than the Mycobacterium tuberculosis complex and Mycobacterium leprae. More than 180 officially recognized NTM species have been identified, with the most frequent human pathogens associated with pulmonary disease (PD) due to NTM belonging to the Mycobacterium avium complex (MAC), followed by M. abscessus (MAB) 1,2 . MAC primarily comprises M. avium and M. intracellulare, and MAB primarily comprises M. abscessus subspecies abscessus (hereafter referred to as M. abscessus) and M. abscessus subspecies massiliense (hereafter referred to as M. massiliense) 1,2 . Despite the global increase in the burden of NTM-PD in recent decades, there is limited information regarding specific biomarkers for distinguishing patients with NTM-PD from healthy individuals or studies of the disease pathophysiology 3,4 .MicroRNAs (miRNAs) are small, 18-25-nucleotide, endogenous, stable, highly conserved noncoding RNAs with important functions in post-transcriptional gene regulation under both physiological and pathological conditions 5,6 . Numerous studies have reported the aberrant expression of several miRNAs in various conditions, including cancer and infectious diseases. miRNAs reportedly play an important regulatory role in the pathogenesis or progression of infectious diseases 7,8 and serve as potential modulators of innate and adaptive immune responses 9,10 . Serum miRNAs are not readily degraded by enzymes, unaffected by changes in temperature and time, and res...

show abstract

MiR-484 promotes non-small-cell lung cancer (NSCLC) progression through inhibiting Apaf-1 associated with the suppression of apoptosis

Cited by 63 publications

References 41 publications

Long non-coding RNA ZFAS1 sponges miR-484 to promote cell proliferation and invasion in colorectal cancer

Long non-coding RNA ZFAS1 sponges miR-484 to promote cell proliferation and invasion in colorectal cancer

High serum miR‑484 expression is associated with the diagnosis and prognosis of patients with non‑small cell lung cancer

miRNA Expression Profiles and Potential as Biomarkers in Nontuberculous Mycobacterial Pulmonary Disease

Contact Info

Product

Resources

About